Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Common Equity (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Common Equity for 15 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 77.91% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Sep 2025, down 77.91%, and an annual FY2024 reading of $8.5 million, down 14.72% over the prior year.
  • Common Equity was $2.2 million for Q3 2025 at BioRestorative Therapies, down from $4.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $14.5 million in Q1 2024 and bottomed at -$4.9 million in Q3 2021.
  • Average Common Equity over 5 years is $6.6 million, with a median of $8.5 million recorded in 2024.
  • The sharpest move saw Common Equity skyrocketed 909.82% in 2021, then plummeted 78.24% in 2023.
  • Year by year, Common Equity stood at $10.8 million in 2021, then dropped by 4.57% to $10.3 million in 2022, then decreased by 2.78% to $10.0 million in 2023, then fell by 14.72% to $8.5 million in 2024, then tumbled by 74.13% to $2.2 million in 2025.
  • Business Quant data shows Common Equity for BRTX at $2.2 million in Q3 2025, $4.8 million in Q2 2025, and $6.1 million in Q1 2025.